Metomidate-based imaging of adrenal masses

Area of Science:

• Nuclear Medicine
• Oncology
• Endocrinology

Background:

• Adrenal tumors are increasingly detected, posing diagnostic challenges, especially in patients with known malignancies.
• Conventional imaging and fine needle biopsy have limitations in accurately characterizing adrenal lesions.
• Distinguishing between adrenocortical and non-adrenocortical lesions, including metastases, remains difficult.

Purpose of the Study:

• To evaluate the utility of metomidate-based radiotracers for noninvasive adrenal lesion characterization.
• To assess the specificity and accuracy of these tracers in differentiating adrenal tumor types.
• To highlight the role of metomidate imaging as a complementary diagnostic tool.

Main Methods:

• Development and application of radiolabeled metomidate tracers for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging.
• Utilizing the high affinity of metomidate for CYP11B enzymes, exclusively expressed in adrenocortical cells.
• Comparing the diagnostic performance of (11)C-metomidate PET and (123)I-iodometomidate SPECT with other imaging modalities.

Main Results:

• Metomidate tracers demonstrate high specificity for adrenocortical neoplasia due to targeted uptake in CYP11B-expressing cells.
• (11)C-metomidate PET and (123)I-iodometomidate SPECT can effectively differentiate between adrenocortical and non-adrenocortical lesions.
• These tracers are capable of visualizing metastases from adrenocortical carcinoma, and (131)I-iodometomidate shows potential for radiotherapy.

Conclusions:

• Metomidate-based imaging provides a specific and noninvasive approach to diagnosing indeterminate adrenal lesions.
• This technique complements conventional methods, improving the accuracy of adrenal tumor characterization.
• Metomidate tracers are valuable tools in managing patients with adrenal tumors, including adrenocortical carcinoma.